Filing Flows › Comparisons › PTN vs TOVX
Palatin Technologies vs Theriva Biologics: PTN and TOVX compared
Palatin Technologies is the larger company: $301K of revenue in its latest quarter (Q4 FY26) against $300K for Theriva Biologics (Q1 2026).
Where the money goes: PTN and TOVX
Palatin Technologies (PTN) · Q4 FY26
Palatin Technologies, Q4 FY26: revenue $301K, net loss $4.4M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Theriva Biologics (TOVX) · Q1 2026
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Palatin Technologies (PTN) | Theriva Biologics (TOVX) | |
|---|---|---|
| Latest quarter | Q4 FY26 | Q1 2026 |
| Revenue | $301K | $300K |
| Operating margin | n/m | -709.0% |
| Net earnings | −$4.4M | −$2.0M |
| Net margin | — | -681.3% |
| Operating cash flow | −$2.7M | −$2.5M |
Questions
Which is bigger, Palatin Technologies or Theriva Biologics?
Palatin Technologies is the larger company: $301K of revenue in its latest quarter (Q4 FY26) against $300K for Theriva Biologics (Q1 2026).
More: Palatin Technologies earnings · how Palatin Technologies makes money · Theriva Biologics earnings · how Theriva Biologics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Sep 28, 2026; 10-Q filed May 5, 2026). Fiscal quarters can end on different dates. Not investment advice.